Abeona Therapeutics Announces first patient treatment with Zevaskyn gene therapy for recessive dystrophic epidermolysis bullosa
Abeona Therapeutics Inc. announced the first patient treatment with FDA-approved Zevaskyn (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive… read more.
